Modulation of carbonic anhydrase 9 (CA9) in human brain cancer

Current Pharmaceutical Design

Volumn 16, Issue 29, 2010, Pages 3288-3299

  Said, Harun M ^a   Supuran, Claudiu T ^b   Hageman, Carsten ^a   Staab, Adrian ^a,c   Polat, Buelent ^a   Katzer, Astrid ^a   Scozzafava, Andrea ^b   Anacker, Jelena ^a   Flentje, Michael ^a   Vordermark, Dirk ^a,d  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF FLORENCE   (Italy)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Brain tumour; CA inhibitors (CAI); CA9; GBM; Glycolysis; Hif 1 ; LGA; Sulfonamide derivatives; Tumour therapy

Indexed keywords

ACETAZOLAMIDE; ANTINEOPLASTIC AGENT; BENZENESULFONAMIDE DERIVATIVE; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; ETHOXZOLAMIDE; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SMALL INTERFERING RNA; SULFONAMIDE;

ALZHEIMER DISEASE; ARTICLE; BIOAVAILABILITY; BRAIN CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL METABOLISM; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPILEPSY; GLAUCOMA; GLIOBLASTOMA; GLUCOSE METABOLISM; HUMAN; IN VITRO STUDY; MALARIA; METASTASIS; NEUROMODULATION; NEUROPATHIC PAIN; PERIODONTITIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANOXIA; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; GLYCOLYSIS; HUMANS; MODELS, BIOLOGICAL; SULFONAMIDES;

EID: 78649914989     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793429788     Document Type: Article

References (141)

1. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000; 6: 157-62.
2. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L. Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA 1997; 94(11): 5667-72.
3. Pagé EL, Robitaille GA, Pouysségur J, Richard DE. Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem 2002; 277(50): 48403-9.
4. Guppy M. The hypoxic core: a possible answer to the cancer paradox. Biochem Biophys Res Commun 2002; 299(4): 676-80.
5. Qu X, Xiao D, Weber HC. Human gastrin-releasing peptide receptor mediates sustained CREB phosphorylation and transactivation in HuTu 80 duodenal cancer cells. FEBS Lett 2002; 527(1-3): 109-13.
6. Angst E, Sibold S, Tiffon C, et al. Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer. Br J Cancer 2006; 95(3): 307-13.
7. Elstner A, Holtkamp N, von Deimling A. Involvement of HIF-1 in desferrioxamine-induced invasion of glioblastoma cells. Clin Exp Metastasis 2007; 24(1): 57-66.
8. Hodges TW, Hossain CF, Kim YP, Zhou YD, Nagle DG. Molecular-targeted antitumor agents: the Saururus cernuus dineolignans manassantin B and 4-demethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1. J Nat Prod 2004; 67(5): 767-71.
9. Turcotte ML, Parliament M, Franko A, Allalunis-Turner J. Variation in mitochondrial function in hypoxia-sensitive and hypoxiatolerant human glioma cells. Br J Cancer 2002; 86(4): 619-24
10. 2 transport to tumors by threedimensional networks of microvessels. Adv Exp Med Biol 1998; 454: 629-34.
11. El-Kareh AW, Secomb TW. Theoretical models for drug delivery to solid tumors. Crit Rev Biomed Eng 1997; 25 (6): 503-71.
12. Yoshida D, Kim K, Noha M, Teramoto A. Anti-apoptotic action by hypoxia inducible factor 1-alpha in human pituitary adenoma cell line, HP-75 in hypoxic condition. J Neurooncol 2006; 78(3): 217-25.
13. Yoshida D, Kim K, Noha M, Teramoto A. Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells. J Neurooncol 2006; 76(1): 13-21.
14. Brown JM. Tumor microenvironment and the response to anticancer therapy. Cancer Biol Ther 2002; 1(5): 453-8.
15. 2 tension. Proc Natl Acad Sci USA 1995; 92(12): 5510-4.
16. Iwai K, Yamanaka K, Kamura T, et al. Identification of the von hippel lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 1999; 96, 12436-12441.
17. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W. The von hippel-lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Develop 1999; 13: 1822-33.
18. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von hippel-lindau tumor suppressor protein. J Biol Chem 2000; 275: 25733-41.
19. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1alpha ubiquitination by a reconstituted von hippel-lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000; 97: 10430-5.
20. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxiainducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2: 423-7.
21. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von hippel-lindau tumor suppressor protein. EMBO J 2000; 19(16): 4298-309.
22. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995; 182(6): 1683-93.
23. Dachs GU, Patterson AV, Firth JD, et al Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3(5): 515-20.
24. Gu YZ, Hogenesch JB, Bradfield CA. The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharm Toxicol 2000; 40: 519-61.
25. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redoxsensitive stabilization of Its α subunit. J Biol Chem 1996; 271: 32253-9.
26. Kuphal S, Winklmeier A, Warnecke C, Bosserhoff AK. Constitutive HIF-1 activity in malignant melanoma. Eur J Cancer 2010; 46(6): 1159-69.
27. Lal A, Peters H, St Croix B, et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 2001; 93(17): 1337-43.
28. Pastorek J, Pastoreková S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment 1994; 9: 2788-888.
29. Závada J, Závadová Z, Pastoreková S, Ciampor F, Pastorek J, Zelník V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 1993; 54(2): 268-74.
30. Hynninen P, Hämäläinen JM, Pastorekova S, et al. Transmembrane carbonic anhydrase isozymes IX and XII in the female mouse reproductive organs. Reprod Biol Endocrinol 2004; 17(2): 73.
31. Pastorekova S, Zavada J. Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy. Cancer Ther 2004; 2: 245-62.
32. Thiry A, Dogné JM, Masereel B, Supuran CT. Targeting tumorassociated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006; 27(11): 566-73.
33. Supuran CT (2004) Carbonic anhydrases: catalytic and inhibition mechanisms, distribution and physiological roles. In: Carbonic Anhydrase. Its Inhibitors and Activators (Supuran, C.T. et al., Eds), pp. 1-23, CRC Press
34. Svastová E, Hulíková A, Rafajová M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004; 577(3): 439-45.
35. Said HM, Staab A, Hagemann C, et al. Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines. J Neurooncol 2007; 81(1): 27-38.
36. Said HM, Polat B, Staab A, et al. Rapid detection of the hypoxia regulated CA-IX and NDRG1 gene expression in different glioblatoma cells in vitro. Oncol Rep 2008; 20: 413-9.
37. Said HM, Hagemann C, Staab A, et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol 2007; 83(3): 398-405.
38. Vordermark D, Brown JM. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol 2003; 179(12): 801-11.
39. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104(49): 19345-50.
40. Bannasch P. Modulation of carbohydrate metabolism during carcinogenesis. Cancer Detect Prev 1986; 9(3-4): 243-9.
41. Lamari F, La Schiazza R, Guillevin R, et al. Biochemical exploration of energetic metabolism and oxidative stress in low grade gliomas: central and peripheral tumor tissue analysis. Ann Biol Clin 2008; 66(2): 143-50.
42. Rhodes CG, Wise RJ, Gibbs JM, et al. In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 1983; 14: 614-26.
43. Miccoli L, Oudard S, Sureau F, Poirson F, Dutrillaux B, Poupon MF. Intracellular pH governs the subcellular distribution of hexokinase in a glioma cell line. Biochem J 1996; 313 (Pt3): 957-62.
44. Oudard S, Arvelo F, Miccoli L, et al. High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer 1996; 74(6): 839-45.
45. Oudard S, Boitier E, Miccoli L, Rousset S, Dutrillaux B, Poupon MF. Gliomas are driven by glycolysis putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res 1997; 17(3C): 1903-11.
46. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202(3): 654-62.
47. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25(34): 4633-46.
48. Harris RA, Bowker-Kinley MM, Huang B, Wu P. Regulation of the activity of the pyruvate dehydrogenase complex. Adv Enzyme Regul 2002; 42: 249-59.
49. th Ed. New York: Lippincott- Raven 1999; pp. 637-69.
50. Schmaltz C, Hardenbergh PH, Wells A, Fisher DE. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol 1998; 18(5): 2845-54.
51. Staab A, Löffler J, Said HM, et al. Modulation of glucose metabolism inhibits hypoxic accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha). Strahlenther Onkol 2007; 183(7): 366-73
52. Nodin C, Nilsson M, Blomstrand F. Gap junction blockage limits intercellular spreading of astrocytic apoptosis induced by metabolic depression. J Neurochem 2005; 94(4): 1111-23.
53. Mateo J, García-Lecea M, Cadenas S, Hernández C, Moncada S. Regulation of hypoxia-inducible factor-1alpha by nitric oxide through mitochondria-dependent and -independent pathways. Biochem J 2003; 376(Pt 2): 537-44.
54. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9(2): 802-11.
55. Brizel DM, Schroeder T, Scher RL, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in headand-neck cancer. Int J Radiat Oncol Biol Phys 2001; 51(2): 349-53.
56. Galarraga J, Loreck DJ, Graham JF, et al. Glucose metabolism in human gliomas: correspondence of in situ and in vitro metabolic rates and altered energy metabolism. Metab Brain Dis 1986; 1(4): 279-91.
57. Isidoro A, Casado E, Redondo A, et al. Breast carcinomas fulfil the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005; 26(12): 2095-104
58. Kwon SJ, Lee YJ. Effect of low glutamine/glucose on hypoxiainduced elevation of hypoxia-inducible factor-1alpha in human pancreatic cancer MiaPaCa-2 and human prostatic cancer DU-145 cells. Clin Cancer Res 2005; 11(13): 4694-700.
59. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res 2005; 65(16): 7259-66.
60. Vordermark D, Kraft P, Katzer A, Bolling T, Willner J, Flentje M. Glucose requirement for hypoxic accumulation of hypoxiainducible factor-1α (HIF-1 α). Cancer Lett 2005; 230: 122-33.
61. Griffiths JR, McSheehy PM, Robinson SP, et al. Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1β (HIF-1 β): evidence of an anabolic role for the HIF-1 pathway. Cancer Res 2002; 62: 688-95.
62. Yasuda S, Arii S, Mori A, et al. Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor-1α and its significance. J Hepatol 2004; 40: 117-23.
63. 2 in hypoxia by nitric oxide: effect on HIF1alpha. Science 2003; 302: 1975-8.
64. Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 2002; 277: 23111-5.
65. Liu L, Simon C. Regulation of transcription and translation by hypoxia. Cancer Biol Ther 2004; 3: 492-7.
66. Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol Cell 2006; 21: 521-31.
67. Faulhammer F, Konrad G, Brankatschk B, Tahirovic S, Knödler A, Mayinger P. Cell growth-dependent coordination of lipid signaling and glycosylation is mediated byinteractions between Sac1p and D pm1p. J Cell Biol 2005; 168: 185-91.
68. Maher JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2 deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 2004; 53: 116-22.
69. Varshney R, Dwarakanath B, Jain V. Radiosensitization by 6- aminonicotinamide and 2-deoxy D glucose in human cancer cells. Int J Radiat Biol 2005; 81: 397-408.
70. Yun H, Lee M, Kim SS, Ha J. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J Biol Chem 2005; 280: 9963-72.
71. 2 mediate glucose deprivation-induced cytotoxicity and oxidative stress in human cancer cells. J Biol Chem 2005; 280: 4254-63.
72. Semenza GL, Roth PH, Fang HM, Wang LW. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxiainducible factor 1. J Biol Chem 1994; 269: 23757-63.
73. Harris RA, Bowker-Kinley MM, Hyang B, Wu P. Regulation of the activity of the pyruvate dehydrogenase complex. Adv Enzyme Regul 2002; 42: 249-59.
74. Holbrook JJ, Gutfreund H. Approaches to the study of enzyme mechanisms lactate dehydrogenase. FEBS Lett 1973; 15; 31(2): 157-69.
75. Vordermark D, Kaffer A, Riedl S, Katzer A, Flentje, M. Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. Int J Radiat Oncol Biol Phys 2005; 61: 1197-207.
76. Kung AL, Zabludoff SD, France DS, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004; 6: 33-43
77. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2004; 3: 233-44.
78. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004; 5: 429-41
79. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 2000; 6(1): 15-9.
80. Wykoff CC, Beasley N, Watson P, et al. Hypoxia-inducible regulation of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 7075-83.
81. Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors: aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors. J Enzyme Inhib 2000; 15(6): 597-610.
82. De Simone G, Vitale RM, Di Fiore A, et al. Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J Med Chem 2006; 49(18): 5544-51.
83. Hilvo M, Supuran CT, Parkkila S. Characterization and inhibition of the recently discovered carbonic anhydrase isoforms CA XIII, XIV and XV. Curr Top Med Chem 2007; 7(9): 893-9.
84. Supuran C. Carbonic anhydrases-an overview. Curr Pharm Des 2008; 14(7): 603-14.
85. Chrastina A, Závada J, Parkkila S, et al. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 2003; 105(6): 873-81.
86. Thiry A, Supuran CT, Masereel B, Dogné JM. Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem 2008; 51(11): 3051-6.
87. Teicher BA, Liu SD, Liu JT, Holden SA, Herman TS. Carbonic Anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res 1993; 13: 1549-56
88. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7(2): 168-81.
89. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003; 23: 146-89.
90. rd ed. New York: Freeman and company 1988; pp. 420-1.
91. Pfeiffer T, Schuster S, Bonhoeffer S. Cooperation and competition in the evolution of ATP-producing pathways. Science 2001; 292: 504-7.
92. Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer 2003; 89: 1375-82.
93. Mangiardi JR, Yodice P. Metabolism of the malignant astrocytoma. Neurosurgery 1990; 26: 1-19.
94. Nagamatsu S., Nakamichi Y., Inoue N., Inoue M., Nishino H, Sawa H. Rat C6 glioma cell growth is related to glucose transport and metabolism. Biochem J 1996; 319 (Pt 2): 477-82.
95. Roslin M, Henriksson R, Bergstrom P, Ungerstedt U, Bergenheim AT. Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol 2003; 61: 151-60.
96. Floridi A, Paggi MG, Fanciulli M. Modulation of glycolysis in neuroepithelial tumors. J Neurosurg Sci 1989; 33: 55-64.
97. Mies G, Paschen W, Ebhardt G, Hossmann KA. Relationship between of blood flow, glucose metabolism, protein synthesis, glucose and ATP content in experimentally-induced glioma (RG1 2.2) of rat brain. J Neurooncol 1990; 9: 17-28.
98. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997; 89: 1763-73.
99. Vazquez A, Liu J, Zhou Y, Oltvai ZN. Catabolic efficiency of aerobic glycolysis: The Warburg effect revisited. BMC Syst Biol 2010; 6: 4(1): 58.
100. Burk D, Woods M, Hunter J. On the significance of glycolysis for cancer growth, with special reference to Morris rat hepatomas. J Natl Cancer Inst 1967; 38: 839-63.
101. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 309-19
102. Greene AE, Todorova MT, Seyfried TN. Perspectives on the metabolic management of epilepsy through dietary reduction ofglucose and elevation of ketone bodies. J Neurochem 2003; 86: 529-37.
103. Strohman R. Maneuvering in the complex path from genotype to phenotype. Science 2002; 296: 701-3.
104. Kacser H, Burns JA. The molecular basis of dominance. Genetics 1981; 97: 639-66.
105. Greenspan RJ. The flexible genome. Nat Rev Genet 2001; 2: 383-7.
106. Seyfried TN, Mukherjee P, Adams E, Mulroony T, Abate LE. Metabolic control of brain cancer: Role of glucose and ketone bodies. Proc Am Assoc Cancer Res 2005; 46: 1147.
107. Akutagawa O, Nishi H, Kyo S, et al. Early growth response-1 mediates downregulation of telomerase in cervical cancer. Cancer Sci 2008; 99(7): 1401-6.
108. Ellen T, Ke Q, Zhang P, Costa M. NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis 2008; 29(1): 2-8.
109. Zhang P, Tchou-Wong KM, Costa M. Egr-1 mediates hypoxiainducible transcription of the NDRG1 gene through an overlapping Egr-1/Sp1 binding site in the promoter. Cancer Res 2007; 67(19): 9125-33.
110. Said HM, Polat B, Hagemann C, et al. Egr-1 is not up-regulated in response to Hypoxic and oxygenation conditions in Human Glioblastoma-in vitro. Mol Med Rep 2009; 2: 757-63.
111. Hilvo M, Innocenti A, Monti SM, De Simone G, Supuran CT, Parkkila S. Recent advances in research on the most novel carbonic anhydrases, CA XIII and XV. Curr Pharm Des 2008; 14(7): 672-8.
112. De Simone G, Di Fiore A, Supuran CT. Are carbonic anhydrase inhibitors suitable for obtaining antiobesity drugs?. Curr Pharm Des 2008; 14(7): 655-60.
113. Temperini C, Scozzafava A, Supuran CT. Carbonic anhydrase activation and the drug design. Curr Pharm Des 2008; 14(7): 708-15.
114. Supuran CT. Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des 2008; 14(7): 641-8
115. Krungkrai J, Supuran CT. The alpha-carbonic anhydrase from the malaria parasite and its inhibition. Curr Pharm Des 2008; 14(7): 631-40
116. Newman LC, Broner SW, Lay CL. Reversible anorgasmia with topiramate therapy for migraine. Neurology 2005; 65(8): 1333-4
117. Kurtiş B, Tüter G, Serdar M, Pinar S, Demirel I, Toyman U. Gingival crevicular fluid prostaglandin E(2) and thiobarbituric acid reactive substance levels in smokers and non-smokers with chronic periodontitis following phase I periodontal therapy and adjunctive use of flurbiprofen. J Periodontol 2007; 78(1): 104-11.
118. Einarsdóttir AB, Stefánsson E. Prevention of diabetic retinopathy. Lancet 2009; 373(9672): 1316-8.
119. Asiedu M, Ossipov MH, Kaila K, Price TJ. Acetazolamide and midazolam act synergistically to inhibit neuropathic pain. Pain 2010; 148(2): 302-8.
120. Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 2008; 14(7): 685-98.
121. Singh-Gupta V, Zhang H, Banerjee S, et al. Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells. Int J Cancer 2009; 124(7): 1675-84.
122. Wang XH, Cavell BE, Syed Alwi SS, Packham G. Inhibition of hypoxia inducible factor by phenethyl isothiocyanate. Biochem Pharmacol 2009; 78(3): 261-72
123. Wang XH, Chen SF, Jin HM, Hu RM. Differential analyses of angiogenesis and expression of growth factors in micro- and macrovascular endothelial cells of type 2 diabetic rats. Life Sci 2009; 84(7-8): 240-9.
124. Cook KM, Hilton ST, Mecinovic J, Motherwell WB, Figg WD, Schofield CJ. Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1α) and p300 by a zinc ejection mechanism. J Biol Chem 2009; 284(39): 26831-8
125. Staab A, Loeffler J, Said HM, et al. Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer 2007; 7: 213.
126. Bryant CS, Munkarah AR, Kumar S, et al. Reduction of hypoxiainduced angiogenesis in ovarian cancer cells by inhibition of HIF-1 alpha gene expression. Arch Gynecol Obstet 2010; In Press
127. Bartholomeusz G, Cherukuri P, Kingston J, et al. In vivo therapeutic silencing of hypoxia-inducible factor 1α (HIF-1α) using singlewalled carbon nanotubes noncovalently coated with siRNA. Nano Res 2009; 2(4): 279-91.
128. Kamlah F, Eul BG, Li S, et al. Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. Cancer Gene Ther 2009; 16(3): 195-205.
129. Takahashi Y, Nishikawa M, Takakura Y. Inhibition of tumor cell growth in the liver by RNA interference-mediated suppression of HIF-1α expression in tumor cells and hepatocytes. Gene Ther 2008; 15(8): 572-82.
130. Jiang M, Wang B, Wang C, et al. Inhibition of hypoxia-inducible factor-1alpha and endothelial progenitor cell differentiation by adenoviral transfer of small interfering RNA in vitro. J Vasc Res 2006; 43(6): 511-21.
131. Mizuno T, Nagao M, Yamada Y, et al. Small interfering RNA expression vector targeting hypoxia-inducible factor 1α inhibits tumor growth in hepatobiliary and pancreatic cancers. Cancer Gene Ther 2006; 13(2): 131-40.
132. Viñas-Castells R, Beltran M, Valls G, et al. The hypoxia-controlled FBXL14 ubiquitin ligase targets SNAIL1 for proteasome degradation. J Biol Chem 2010; 285(6): 3794-805.
133. Berchner-Pfannschmidt U, Petrat F, Doege K, et al. Chelation of cellular calcium modulates hypoxia-inducible gene expression through activation of hypoxia-inducible factor-1alpha. J Biol Chem 2004; 279(43): 44976-86.
134. Berchner-Pfannschmidt U, Wotzlaw C, Merten E, Acker H, Fandrey J. Visualization of the three-dimensional organization of hypoxia-inducible factor-1 alpha and interacting cofactors in subnuclear structures. Biol Chem 2004; 385(3-4): 231-7.
135. Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg Med Chem Lett 2004; 14(21): 5427-33.
136. Semenza GL.Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3(10): 721-732
137. Said HM, Stein S, Hagemann C, et al. Oxygen-dependent regulation of NDRG1 in human glioblastoma cells in vitro and in vivo. Oncol Rep 2009; 21(1): 237-246.
138. Akslen LA, Andersen KJ, Bjerkvig R. Characteristics of human and rat glioma cells grown in a defined medium. Anticancer Res 1988; 8: 797-803.
139. Pastorekova S, Zatovicova M, Pastorek J. Cancer-associated carbonic anhydrases and their inhibition. Curr Pharm Des 2008; 14(7): 685-698.
140. Supuran CT. Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des 2008; 14(7): 641-648.
141. Supuran CT. Carbonic anhydrases--an overview. Curr Pharm Des 2008; 14(7): 603-614.